PMID- 33587304
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1439-0272 (Electronic)
IS  - 0303-4569 (Linking)
VI  - 53
IP  - 4
DP  - 2021 May
TI  - Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or 
      combination in treating erectile dysfunction: A systematic review and 
      meta-analysis of randomised controlled trials.
PG  - e14007
LID - 10.1111/and.14007 [doi]
AB  - The meta-analysis was performed to assess the efficacy and safety of daily oral 
      L-arginine and phosphodiesterase type 5 inhibitors (PDE5Is) alone or combination 
      in treating patients with erectile dysfunction (ED). We performed a search of 
      randomised controlled trials in the following databases: PubMed, EMBASE and 
      Cochrane Library databases. Four articles including 373 patients were studied. 
      Erectile functions were significantly improved in three therapy groups compared 
      with baseline. Patients who received the combination of L-arginine and PDE5Is 
      showed significant improvement compared to those treated with L-arginine and 
      PDE5Is alone, as assessed by sexual function index (p <0.00001 and p =0.005, 
      respectively) and total testosterone (p <0.00001 and p =0.0007, respectively). 
      Furthermore, patients who treated with PDE5Is alone exhibited the better efficacy 
      than those treated with L-arginine alone in respects of sexual function index 
      (p <0.00001) and total testosterone (p =0.0001). However, the combination of 
      L-arginine and PDE5Is had no obvious difference relative to PDE5Is alone in terms 
      of various adverse events (AEs). Conclusively, compared with monotherapy, the 
      combination of L-arginine and PDE5Is showed a greater improvement of sexual 
      function and total testosterone, and did not significantly increase the AEs. 
      Besides, PDE5Is alone revealed a better effect than those treated with L-arginine 
      alone for patients with ED.
CI  - (c) 2021 Wiley-VCH GmbH.
FAU - Xu, Zhunan
AU  - Xu Z
AD  - Second Clinical Medical College, Binzhou Medical University, Yantai, China.
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
FAU - Liu, Chu
AU  - Liu C
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, China.
FAU - Liu, Shuang
AU  - Liu S
AD  - School of Rehabilitation Medicine, Binzhou Medical University, Yantai, China.
FAU - Zhou, Zhongbao
AU  - Zhou Z
AUID- ORCID: 0000-0002-9810-8145
AD  - Department of Urology, Beijing TianTan Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210215
PL  - Germany
TA  - Andrologia
JT  - Andrologia
JID - 0423506
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Arginine
MH  - *Erectile Dysfunction/drug therapy
MH  - Humans
MH  - Male
MH  - Penile Erection
MH  - *Phosphodiesterase 5 Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - L-arginine
OT  - PDE5Is
OT  - erectile dysfunction
OT  - randomised controlled trials
OT  - systematic review and meta-analysis
EDAT- 2021/02/16 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/02/15 12:14
PHST- 2021/01/22 00:00 [revised]
PHST- 2020/12/14 00:00 [received]
PHST- 2021/01/25 00:00 [accepted]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/02/15 12:14 [entrez]
AID - 10.1111/and.14007 [doi]
PST - ppublish
SO  - Andrologia. 2021 May;53(4):e14007. doi: 10.1111/and.14007. Epub 2021 Feb 15.